Lipoprotein(a) (Lp(a))

PharmaWatch: Novartis Pays $150 Million to Pursue Transformational Cardiovascular Disease Therapy

Feb 26, 2019 | Cardiovascular, Leading Pharma, Lipoprotein(a) (Lp(a)), Pharma Watch

As reported in West Globe Newswire, Novartis has announced its’ move into developing a targeted cardiovascular therapy by exercising an option to license the rights to develop and commercialize TQJ230, an investigational agent preciously known as AKCEA-APO(a)-LRx,...

TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.

159 WEST BROADWAY SUITE 200
SALT LAKE CITY, UT 84101

PharmaWatch: Novartis Pays $150 Million to Pursue Transformational Cardiovascular Disease Therapy

Pin It on Pinterest